Evidence map›Paper›PMID 21138865›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010

Benign mesenchymal stromal cells in human sarcomas.

Alexei Morozov, Robert J Downey, John Healey, Andre L Moreira, Emil Lou, Anna Franceschino, Yildirim Dogan, Roland Leung, Mark Edgar, Michael LaQuaglia and 2 more

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Endoglin for targeted cancer treatment.Current oncology reports · 2014
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Alexei MorozovDepartments of Cell Biology, Memorial Sloan-Kettering Cancer Center, New York 10065, USA. Alexmorozov1@gmail.com
Robert J Downey
John Healey
Andre L Moreira
Emil Lou
Anna Franceschino
Yildirim Dogan
Roland Leung
Mark Edgar
Michael LaQuaglia
Robert G Maki
Malcolm A S Moore
Memorial Sloan Kettering Cancer Center · US

Funding

Clinical and Translational Science Center (KL2)KL2RR024997 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2007 to 2011
$1.5M
NCRR NIH HHS KL2 RR024997NCRR NIH HHS KL2RR024997
6 · The paper itself

Abstract

purposeRecent evidence suggests that at least some sarcomas arise through aberrant differentiation of mesenchymal stromal cells (MSCs), but MSCs have never been isolated directly from human sarcoma specimens. EXPERIMENTAL

designWe examined human sarcoma cell lines and primary adherent cultures derived from human sarcoma surgical samples for features of MSCs. We further characterized primary cultures as either benign or malignant by the presence of tumor-defining genetic lesions and tumor formation in immunocompromised mice.

resultsWe show that a dedifferentiated liposarcoma cell line DDLS8817 posesses fat, bone, and cartilage trilineage differentiation potential characteristic of MSCs. Primary sarcoma cultures have the morphology, surface immunophenotype, and differentiation potential characteristic of MSCs. Surprisingly, many of these cultures are benign, as they do not form tumors in mice and lack sarcoma-defining genetic lesions. Consistent with the recently proposed pericyte origin of MSCs in normal human tissues, sarcoma-derived benign MSCs (SDBMSCs) express markers of pericytes and cooperate with endothelial cells in tube formation assays. In human sarcoma specimens, a subset of CD146-positive microvascular pericytes expresses CD105, an MSC marker, whereas malignant cells largely do not. In an in vitro coculture model, SDBMSCs as well as normal human pericytes markedly stimulate the growth of sarcoma cell lines.

conclusionsSDBMSCs/pericytes represent a previously undescribed stromal cell type in sarcoma that may contribute to tumor formation.

Indexed as

AnimalsCell DifferentiationCell Line, TumorCell SeparationDrug Evaluation, PreclinicalFemaleHumansInterleukin Receptor Common gamma SubunitMesenchymal Stem CellsMiceMice, Inbred NODMice, SCIDMice, TransgenicSarcomaStromal CellsTransplantation, HeterologousIl2rg protein, mouseInterleukin Receptor Common gamma Subunit

Identifiers

PMID21138865
PMCPMC3820159
OpenAlexW2097791730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.